2000-2014世界癌症生存率和中國癌症生存率權威數據文獻

來自專欄基於基因組學診斷的癌症靶向治療8 人贊了文章

我最近寫了一些文章和評論，下面也有一些知友發表自己的見解，我非常歡迎。有時候我發現大家爭來爭去其實沒有什麼意思，因為絕大多數人都沒有實錘的數據來支持自己的觀點，如果大家能仔細閱讀最新和最權威的醫學數據再討論，這樣可以節省很多不必要的紛爭。

關於歐美髮達國家的數據，今年柳葉刀雜誌發表了2000-2014年世界71個國家的數據，其中也有中國，但是不是全國性的數據，所以比較中國和其他國家的時候需要參考單獨報道中國全國數據的文獻。

結果如下：

Findings

For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010–14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 33·4%, and 24·8%). For children diagnosed during 2010–14, 5-year survival for acute lymphoblastic leukaemia ranged from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark).

下面的文章介紹中國癌症的全國性統計數據, 2016年發表， 超過1600個引用：

Abstract

With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. Because of Chinas massive population (1.37 billion), previous national incidence and mortality estimates have been limited to small samples of the population using data from the 1990s or based on a specific year. With high‐quality data from an additional number of population‐based registries now available through the National Central Cancer Registry of China, the authors analyzed data from 72 local, population‐based cancer registries (2009‐2011), representing 6.5% of the population, to estimate the number of new cases and cancer deaths for 2015. Data from 22 registries were used for trend analyses (2000‐2011). The results indicated that an estimated 4292,000 new cancer cases and 2814,000 cancer deaths would occur in China in 2015, with lung cancer being the most common incident cancer and the leading cause of cancer death. Stomach, esophageal, and liver cancers were also commonly diagnosed and were identified as leading causes of cancer death. Residents of rural areas had significantly higher age‐standardized (Segi population) incidence and mortality rates for all cancers combined than urban residents (213.6 per 100,000 vs 191.5 per 100,000 for incidence; 149.0 per 100,000 vs 109.5 per 100,000 for mortality, respectively). For all cancers combined, the incidence rates were stable during 2000 through 2011 for males (+0.2% per year; P?=?.1), whereas they increased significantly (+2.2% per year; P?<?.05) among females. In contrast, the mortality rates since 2006 have decreased significantly for both males (?1.4% per year; P?<?.05) and females (?1.1% per year; P?<?.05). Many of the estimated cancer cases and deaths can be prevented through reducing the prevalence of risk factors, while increasing the effectiveness of clinical care delivery, particularly for those living in rural areas and in disadvantaged populations.

兩篇文章數據量很大，讀起來非常枯燥，很多有爭議性的問題，這兩篇文章裡面都有答案。如果你是一個嚴肅的醫療行業從業者， 又或者有生物學背景， 既有興趣又有時間，不妨一讀。